CARL ZEISS MEDITEC AG |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.35 EUR | -1.43% |
|
-21.07% | -32.85% |
| 06-19 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades |  |
| 06-18 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The firm trades with high earnings multiples: 28.42 times its 2024 earnings per share.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -32.85% | 6.33B | - | ||
| +4.98% | 213B | B | ||
| +7.44% | 184B | B- | ||
| +28.22% | 153B | B- | ||
| +33.19% | 113B | A- | ||
| +1.22% | 63.66B | A- | ||
| +16.51% | 53.53B | B+ | ||
| +1.45% | 49.11B | B+ | ||
| -4.53% | 38.73B | A | ||
| +2.74% | 36.26B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AFX Stock
- AFX Stock
- Ratings Carl Zeiss Meditec AG
